Psoriasis Raptiva

More on PSORIASIS ...
What Is Psoriasis?
Psoriasis is a chronic (long-lasting) skin disease of scaling and inflammation that affects 2 to 2.6 percent of the United States population, or between 5.8 and 7.5 million people. Although the disease occurs in all age groups, it primarily affects adults. It appears about equally in males and females. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature. Usually this movement (also called turnover) takes about a month, but in psoriasis it may occur in only a few days. In its typical form, psoriasis results in patches of thick, red (inflamed) skin covered with silvery scales. These patches, which are sometimes referred to as plaques, usually itch or feel sore. They most often occur on the elbows, knees, other parts of the legs, scalp, lower back, face, palms, and soles of the feet, but they can occur on skin anywhere on the body.

The disease (psoriasis) may also affect the fingernails, the toenails, and the soft tissues of the genitals and inside the mouth. While it is not unusual for the skin around affected joints to crack, approximately 1 million people with psoriasis experience joint inflammation that produces symptoms of arthritis. This condition is called psoriatic arthritis. - NIAMS

Top Resource Searches For:

Psoriasis Raptiva

Marketed Product: RAPTIVA_
... " RAPTIVA_ Product. " Psoriasis Facts ... in the reduction of symptoms associated with psoriasis. RAPTIVA is administered once-weekly via subcutaneous injection ...

CommentWire by Datamonitor - Psoriasis: Raptiva nears kick-off
Breaking news with business, finance, company and internet comment articles with opinion and analysis of the latest stories ... Psoriasis: Raptiva nears kick-off ... 1:20 PM GMT (Datamonitor) - The launch of Raptiva for psoriasis will upgrade Xoma's [XOMA] stock and improve its cash ...

Efalizumab (Raptiva) bei Psoriasis
Efalizumab (Raptiva) bei Psoriasis ... Efalizumab (Raptiva®) in der Langzeitbehandlung von Psoriasis ... Wirkstoff: Efalizumab (Raptiva®) ist ein T-Zellmodulator und hemmt die Aktivierung der T-Zellen, die für die ...

National Psoriasis Foundation to Testify for Raptiva Approval
Password. News and Events. News. Federal Advisory Committee Recommends Approval of New Psoriasis Drug. Final approval could come by end of October. First posted Sept. 10, 2003. Last updated Sept. 23, 2003. In a unanimous vote on Sept. ... approval of the psoriasis drug efalizumab (brand name Raptiva) for the treatment of moderate to severe stable plaque psoriasis. The Dermatologic and Ophthalmic ...

RAPTIVA for Psoriasis: FAQs
Common questions about RAPTIVA psoriasis treatment. RAPTIVA for plaque psoriasis brought to you by Genentech.

Psoriasis-Netz - Die vielen Seiten der Schuppenflechte: Startseite
... 26.06.2004. Efalizumab (Raptiva) Psoriasis arthritis ... Empfehlen Sie das Psoriasis-Netz Bekannten oder Patienten ...

Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland
Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland ... First Approval of Raptiva for Serono GENEVA, March 16 /PRNewswire-FirstCall ... to-severe plaque psoriasis. Raptiva is the first biological therapy for psoriasis that is approved ...

DERMATOLOGIC AND OPTHALMIC DRUGS ADVISORY COMMITTEE MEETING
... Clinical Development of Raptiva: Completed Psoriasis Studies...... 23 ... be safe and effective for the treatment of psoriasis. Raptiva has a rapid onset of action and is well ...

Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland - ADVFN News ...
... Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in ... severe plaque psoriasis. Raptiva is the first biological therapy for psoriasis that is ...

RAPTIVA_ — Psoriasis Facts
(Efalizumab) Psoriasis Facts. Psoriasis is a chronic skin disorder that affects approximately 4.5 million people in the United States, according to the National Psoriasis Foundation.

Genentech: Products - Product Information - RAPTIVA
... RAPTIVA is approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults ... of symptoms associated with psoriasis. RAPTIVA is administered once-weekly via ...

Chronic Pain | Psoriasis Raptiva